zum Inhalt springen

Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Single-cell-resolved interspecies comparison shows a shared inflammatory axis and a dominant neutrophil-endothelial program in severe COVID-19 (2024)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Peidli, Stefan
    Nouailles, Geraldine
    Wyler, Emanuel
    Adler, Julia M.
    Kunder, Sandra
    Voß, Anne
    Kazmierski, Julia
    Pott, Fabian
    Pennitz, Peter
    Postmus, Dylan
    Teixeira Alves, Luiz Gustavo
    Goffinet, Christine
    Gruber, Achim D. (WE 12)
    Blüthgen, Nils
    Witzenrath, Martin
    Trimpert, Jakob
    Landthaler, Markus
    Praktiknjo, Samantha D.
    Quelle
    Cell reports
    Bandzählung: 43
    Heftzählung: 6
    Seiten: 114328
    ISSN: 2211-1247
    Sprache
    Englisch
    Verweise
    URL (Volltext): https://www.sciencedirect.com/science/article/pii/S2211124724006569?via%3Dihub
    DOI: 10.1016/j.celrep.2024.114328
    Pubmed: 38861386
    Kontakt
    Institut für Tierpathologie

    Robert-von-Ostertag-Str. 15
    14163 Berlin
    +49 30 838 62450
    pathologie@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    A key issue for research on COVID-19 pathogenesis is the lack of biopsies from patients and of samples at the onset of infection. To overcome these hurdles, hamsters were shown to be useful models for studying this disease. Here, we further leverage the model to molecularly survey the disease progression from time-resolved single-cell RNA sequencing data collected from healthy and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected Syrian and Roborovski hamster lungs. We compare our data to human COVID-19 studies, including bronchoalveolar lavage, nasal swab, and postmortem lung tissue, and identify a shared axis of inflammation dominated by macrophages, neutrophils, and endothelial cells, which we show to be transient in Syrian and terminal in Roborovski hamsters. Our data suggest that, following SARS-CoV-2 infection, commitment to a type 1- or type 3-biased immunity determines moderate versus severe COVID-19 outcomes, respectively.